… We enrolled patients with active rheumatoid arthritis despite … had at least one additional
cardiovascular risk factor (current … , extraarticular rheumatoid arthritis, or history of coronary artery …

… risk factors and cardiovascular risk scores with tofacitinib versus tumour necrosis factor inhibitors
(TNFi) in patients with rheumatoid arthritis … risk factors for cardiovascular risk and cancer…

… risk for the development of malignancies with tofacitinib therapy when compared to treatment
with tumor necrosis factor … who had at least 1 risk factor for cardiovascular disease (pooled …

… Risk of malignancies (excluding non-melanoma skin cancer) and infections was also higher
… reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development …

… A recent RCT comparing tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily and anti-TNF
in rheumatoid arthritis demonstrated an increased risk of MACE HR 1.33 and cancer HR …

… This is a comment on "Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid
Arthritis." N Engl J Med. 2022 May 5;386(18):1766. … COVID-19 outcomes in patients with …

… Rheumatoid arthritis was classified according to the treating physician and/or EULAR/ACR
2010 criteria [2]. Rheumatoid arthritis patients prescribed either tofacitinib … for tofacitinib and …

… rheumatoid arthritis (RA) aged 50 years or older with at least one additional cardiovascular
risk factor received tofacitinib … Post hoc, cumulative probabilities and incidence rates (patients …

… that patients with rheumatoid arthritis (RA) aged ≥50 years with ≥1 … cardiovascular (CV)
risk factor had an increased risk of major adverse cardiovascular events (MACE) with tofacitinib …

… In that study of patients with rheumatoid arthritis with existing cardiovascular risk, tofacitinib,
… Interestingly, this study observed similar malignancy risk between tofacitinib and TNFi …